Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.09
-22.3%
$0.10
$0.06
$0.47
$6.61M0.76570,559 shs2.31 million shs
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
$0.97
-0.5%
$1.27
$0.45
$3.80
$6.37M4.59435,204 shs16,282 shs
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
$0.13
-21.8%
$0.12
$0.10
$2.63
$6.92M1.653.15 million shs4.81 million shs
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
$1.01
-3.8%
$1.20
$5.56
$55.50
$1.69M0.278,831 shs27,598 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%0.00%0.00%-28.54%-73.89%
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
-0.52%-2.53%-28.52%-52.93%-29.04%
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
0.00%0.00%0.00%0.00%-94.08%
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
-3.79%-4.70%-17.20%-41.27%-52.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
1.5299 of 5 stars
3.50.00.00.00.61.70.6
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
2.2506 of 5 stars
3.40.00.00.02.01.71.3
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$2.752,908.75% Upside
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
3.00
BuyN/AN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
2.80
Moderate Buy$9.207,260.00% Upside
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$170K38.87N/AN/A$0.20 per share0.46
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
N/AN/AN/AN/A($1.65) per shareN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
$8.10M0.85N/AN/A$1.05 per share0.12
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$0.31N/AN/AN/A-12,594.21%-421.73%-147.54%N/A
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
-$7.38M-$1.24N/AN/AN/AN/A-453.90%N/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%6/20/2025 (Estimated)
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
-$3.83MN/A0.00N/AN/A-49.09%-43.39%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
N/AN/AN/AN/AN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
N/AN/AN/AN/AN/A
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.05
0.75
0.75
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
N/A
0.60
0.60
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
1.00
1.61
1.61
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
N/A
4.90
4.90

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
77.96%
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
97.47%
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
0.02%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.02%
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
16.40%
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
8.50%
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2072.29 million68.74 millionNot Optionable
Chromocell Therapeutics Co. stock logo
CHRO
Chromocell Therapeutics
46.60 million5.04 millionN/A
Omega Therapeutics, Inc. stock logo
OMGA
Omega Therapeutics
12055.37 million50.66 millionOptionable
PharmaCyte Biotech Inc stock logo
PMCBD
PharmaCyte Biotech
N/A1.67 millionN/ANot Optionable

Recent News About These Companies

PharmaCyte Biotech (PMCB) Earnings Dates & Reports
International Life Sciences & Biotech Conference
PharmaCyte Biotech Inc (PMCB)
Exploring beauty’s biotech frontier
PMCB PharmaCyte Biotech, Inc.
Why Do So Many Biotech Startups Fail?
Baltimore Biotech News
Biotech Study Break
Biden sees future in ag biotech; food safety included
Biotech & Health
BLACK BIRD BIOTECH INC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AIM ImmunoTech stock logo

AIM ImmunoTech NYSE:AIM

$0.09 -0.03 (-22.34%)
As of 04/4/2025
This is a fair market value price provided by Polygon.io. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Chromocell Therapeutics stock logo

Chromocell Therapeutics NYSE:CHRO

$0.96 -0.01 (-0.52%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$0.94 -0.03 (-3.01%)
As of 05/28/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Omega Therapeutics stock logo

Omega Therapeutics NASDAQ:OMGA

$0.12 -0.03 (-21.83%)
Closing price 02/24/2025
Extended Trading
$0.12 0.00 (0.00%)
As of 02/24/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

PharmaCyte Biotech stock logo

PharmaCyte Biotech OTCMKTS:PMCBD

$1.01 -0.04 (-3.79%)
As of 05/27/2025

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.